
The Obesity Revolution
A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as incretin mimetics or GLP-1-based drugs, this medication class is seen as the first of a very long line that could have the medical and societal impact of blockbusters like Viagra, Lipitor, and Prozac. Like them, these weight-loss drugs have the potential to reshape the way we think of what it means to be sick and what it takes to be healthy.
Latest


GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

STAT Plus: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story

STAT Plus: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro

STAT Plus: Here are the dozens of weight loss drugs in development to catch a booming market

STAT Plus: What do new weight loss drugs mean for the future of bariatric surgery?

STAT Plus: Obesity specialists are scarce. Here’s how that’s starting to change

STAT Plus: Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
All Coverage












